Foghorn Therapeutics Earnings Estimate

FHTX Stock  USD 4.31  0.11  2.62%   
The next projected EPS of Foghorn Therapeutics is estimated to be -0.39 with future projections ranging from a low of -0.4475 to a high of -0.3375. Foghorn Therapeutics' most recent 12-month trailing earnings per share (EPS TTM) is at -1.9. Please be aware that the consensus of earnings estimates for Foghorn Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
Foghorn Therapeutics is projected to generate -0.39 in earnings per share on the 31st of December 2024. Foghorn Therapeutics earnings estimates show analyst consensus about projected Foghorn Therapeutics EPS (Earning Per Share). It derives the highest and the lowest estimates based on Foghorn Therapeutics' historical volatility. Many public companies, such as Foghorn Therapeutics, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Foghorn Therapeutics' earnings estimates, investors can diagnose different trends across Foghorn Therapeutics' analyst sentiment over time as well as compare current estimates against different timeframes. Gross Profit is likely to rise to about (64.6 M) in 2025. Pretax Profit Margin is likely to drop to -2.61 in 2025
  
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Foghorn Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Foghorn Stock please use our How to Invest in Foghorn Therapeutics guide.

Foghorn Therapeutics Earnings Estimation Breakdown

The calculation of Foghorn Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Foghorn Therapeutics is estimated to be -0.39 with the future projection ranging from a low of -0.4475 to a high of -0.3375. Please be aware that this consensus of annual earnings estimates for Foghorn Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
-0.31
-0.45
Lowest
Expected EPS
-0.39
-0.34
Highest

Foghorn Therapeutics Earnings Projection Consensus

Suppose the current estimates of Foghorn Therapeutics' value are higher than the current market price of the Foghorn Therapeutics stock. In this case, investors may conclude that Foghorn Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Foghorn Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of December 2024Current EPS (TTM)
674.39%
-0.31
-0.39
-1.9

Foghorn Therapeutics Earnings per Share Projection vs Actual

Actual Earning per Share of Foghorn Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Foghorn Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Foghorn Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Foghorn Therapeutics Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Foghorn Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Foghorn Therapeutics should always be considered in relation to other companies to make a more educated investment decision.

Foghorn Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Foghorn Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-10-31
2024-09-30-0.44-0.310.1329 
2024-08-08
2024-06-30-0.65-0.450.230 
2024-05-06
2024-03-31-0.63-0.590.04
2024-03-07
2023-12-31-0.76-0.570.1925 
2023-11-02
2023-09-30-0.75-0.340.4154 
2023-08-04
2023-06-30-0.73-0.70.03
2023-05-08
2023-03-31-0.72-0.73-0.01
2023-03-09
2022-12-31-0.62-0.69-0.0711 
2022-11-08
2022-09-30-0.62-0.620.0
2022-08-09
2022-06-30-0.59-0.66-0.0711 
2022-05-09
2022-03-31-0.52-0.65-0.1325 
2022-03-10
2021-12-31-0.49-0.74-0.2551 
2021-11-09
2021-09-30-0.67-0.71-0.04
2021-08-10
2021-06-30-0.63-0.630.0
2021-05-11
2021-03-31-0.63-0.620.01
2021-03-18
2020-12-31-0.45-1.86-1.41313 
2020-12-04
2020-09-30-1.72-3.12-1.481 
2020-09-02
2020-06-300-1.29-1.29

About Foghorn Therapeutics Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Foghorn Therapeutics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Foghorn Therapeutics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Foghorn Therapeutics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-424.4 M-403.2 M
Retained Earnings Total Equity-335.8 M-352.6 M
Earnings Yield(0.42)(0.40)
Price Earnings Ratio(2.48)(2.60)
Price Earnings To Growth Ratio 0.23  0.24 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Foghorn Stock Analysis

When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.